Drug Profile
Onvansertib - Cardiff Oncology
Alternative Names: NMS-1286937; NMS-P937; Onvansertib-fumarate; PCM-075; PCM-075HLatest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator Nerviano Medical Sciences
- Developer Cardiff Oncology
- Class Antineoplastics; Piperazines; Pyrazoles; Quinazolines; Small molecules
- Mechanism of Action Polo-like kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia; Colorectal cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer
- Phase I/II Triple negative breast cancer
- Phase I Chronic myelomonocytic leukaemia
- Preclinical Medulloblastoma; Ovarian cancer
- No development reported Lung cancer; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 08 Apr 2024 Efficacy data from a phase Ib/II ONSEMBLE trial in Colorectal cancer released by Cardiff Oncology
- 08 Apr 2024 Pharmacodynamics data from preclinical studies in Ovarian cancer, Colorectal cancer and Small cell lung cancer were released by Cardiff Oncology
- 29 Feb 2024 Cardiff Oncology terminates a phase II CRDF-003 trial in Colorectal cancer (In the elderly, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, In adults, Adjunctive treatment) in USA (PO) to focus on its new lead program in first-line RAS-mutated mCRC (NCT05593328)